US-based biotechnology company RXi Pharmaceuticals has formed a research alliance with the Karolinska Institutet in Stockholm, Sweden, to develop and improve immuno-oncology treatments for solid tumours.
Tumour therapy, particularly in the case of multidrug resistant cancers, could be significantly enhanced by using siRNA to down-regulate the production of proteins involved in cancer cell resistance such as Pgp or survivin...